RA
ANIK icon

Royce & Associates’s Anika Therapeutics ANIK Stock Holding History

Royce & Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,809
Closed -$205K – 970
2021
Q3 		$205K Sell
4,809
-4,167
-46% -$172K ﹤0.01% 970
2021
Q2 		$389K Sell
8,976
-1,752
-16% -$74.6K ﹤0.01% 953
2021
Q1 		$438K Sell
10,728
-3,271
-23% -$124K ﹤0.01% 952
2020
Q4 		$634K Buy
13,999
+78
+0.6% +$2.96K 0.01% 861
2020
Q3 		$493K Sell
13,921
-51
-0.4% -$1.84K 0.01% 865
2020
Q2 		$527K Buy
13,972
+143
+1% +$4.71K 0.01% 852
2020
Q1 		$400K Sell
13,829
-1,210
-8% -$48.9K 0.01% 857
2019
Q4 		$780K Buy
15,039
+31
+0.2% +$1.8K 0.01% 836
2019
Q3 		$824K Buy
15,008
+3,673
+32% +$189K 0.01% 833
2019
Q2 		$460K Buy
11,335
+4,109
+57% +$150K ﹤0.01% 920
2019
Q1 		$219K Buy
7,226
+6,622
+1,096% +$227K ﹤0.01% 995
2018
Q4 		$20K Buy
604
+65
+12% +$2.35K ﹤0.01% 1104
2018
Q3 		$23K Buy
539
+225
+72% +$8.89K ﹤0.01% 1139
2018
Q2 		$10K Buy
314
+166
+112% +$6.84K ﹤0.01% 1201
2018
Q1 		$7K Sell
148
-6
-4% -$339 ﹤0.01% 1219
2017
Q4 		$8K Buy
154
+22
+17% +$1.22K ﹤0.01% 1206
2017
Q3 		$8K Buy
+132
New +$6.9K ﹤0.01% 1187
2016
Q2 		– Sell
-46,465
Closed -$2.08M – 1085
2016
Q1 		$2.08M Sell
46,465
-12,800
-22% -$519K 0.01% 815
2015
Q4 		$2.26M Buy
+59,265
New +$2.27M 0.01% 831
2014
Q3 		– Sell
-1,300
Closed -$60K – 1399
2014
Q2 		$60K Hold
1,300
– – ﹤0.01% 1368
2014
Q1 		$53K Sell
1,300
-300
-19% -$11.2K ﹤0.01% 1373
2013
Q4 		$61K Sell
1,600
-300
-16% -$9.26K ﹤0.01% 1380
2013
Q3 		$46K Hold
1,900
– – ﹤0.01% 1404
2013
Q2 		$32K Buy
+1,900
New +$27.4K ﹤0.01% 1405

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Royce & Associates's ANIK Position: Q4 2021 in Review

Royce & Associates sold out of Anika Therapeutics (ANIK) in Q4 2021, closing a stake of 4,809 shares — an estimated $205K sold.

Royce & Associates first reported a position in ANIK in Q2 2013 and held it in 24 quarters. The position peaked at $2.26M in Q4 2015. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2021.

  • Royce & Associates reported no remaining Anika Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Royce & Associates sold 4,809 Anika Therapeutics shares in Q4 2021, an estimated $205K.
  • Royce & Associates first reported a position in Anika Therapeutics in Q2 2013 and held it in 24 quarters.
  • Royce & Associates's Anika Therapeutics position peaked at $2.26M in Q4 2015.
  • 126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2021.

Based on Royce & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.